Literature DB >> 11707293

The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines.

G Eisenhofer1.   

Abstract

Catecholamines are translocated across plasma membranes by transporters that belong to two large families with mainly neuronal or extraneuronal locations. In mammals, neuronal uptake of catecholamines involves the dopamine transporter (DAT) at dopaminergic neurons and the norepinephrine transporter (NET) at noradrenergic neurons. Extraneuronal uptake of catecholamines is mediated by organic cation transporters (OCTs), including the classic corticosterone-sensitive extraneuronal monoamine transporter. Catecholamine transporters function as part of uptake and metabolizing systems primarily responsible for inactivation of transmitter released by neurons. Additionally, the neuronal catecholamine transporters, recycle catecholamines for rerelease, thereby reducing requirements for transmitter synthesis. In a broader sense, catecholamine transporters function as part of integrated systems where catecholamine synthesis, release, uptake, and metabolism are regulated in a coordinated fashion in response to the demands placed on the system. Location is also important to function. Neuronal transporters are essential for rapid termination of the signal in neuronal-effector organ transmission, whereas non-neuronal transporters are more important for limiting the spread of the signal and for clearance of catecholamines from the bloodstream. Besides their presynaptic locations, NET and DAT are also present at several extraneuronal locations, including syncytiotrophoblasts of the placenta and endothelial cells of the lung (NET), stomach and pancreas (DAT). The extraneuronal monoamine transporter shows a broad tissue distribution, whereas the other two non-neuronal catecholamine transporters (OCT1 and OCT2) are mainly localized to the liver, kidney, and intestine. Altered function of peripheral catecholamine transporters may be involved in disturbances of the autonomic nervous system, such as occurs in congestive heart failure and hypernoradrenergic hypertension. Peripheral catecholamine transporters provide important targets for clinical imaging of sympathetic nerves and diagnostic localization and treatment of neuroendocrine tumors, such as neuroblastomas and pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707293     DOI: 10.1016/s0163-7258(01)00144-9

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  83 in total

1.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

2.  Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).

Authors:  Andreas Lazar; Dirk Gründemann; Reinhard Berkels; Dirk Taubert; Tim Zimmermann; Edgar Schömig
Journal:  J Hum Genet       Date:  2003-04-09       Impact factor: 3.172

Review 3.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

4.  Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.

Authors:  Lucia Martiniova; Susannah Cleary; Edwin W Lai; Dale O Kiesewetter; Jurgen Seidel; Linda F Dawson; Jacqueline K Phillips; David Thomasson; Xiaoyuan Chen; Graeme Eisenhofer; James F Powers; Richard Kvetnansky; Karel Pacak
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

5.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

6.  Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint.

Authors:  Na Feng; Christopher A Lowry; Jodi L Lukkes; Miles Orchinik; Gina L Forster; Kenneth J Renner
Journal:  Brain Res       Date:  2010-02-19       Impact factor: 3.252

7.  Differences in sympathetic neuroeffector transmission to rat mesenteric arteries and veins as probed by in vitro continuous amperometry and video imaging.

Authors:  Jinwoo Park; James J Galligan; Gregory D Fink; Greg M Swain
Journal:  J Physiol       Date:  2007-08-30       Impact factor: 5.182

Review 8.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

Review 9.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

10.  Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts.

Authors:  Nina Kaludercic; Andrea Carpi; Takahiro Nagayama; Vidhya Sivakumaran; Guangshuo Zhu; Edwin W Lai; Djahida Bedja; Agnese De Mario; Kevin Chen; Kathleen L Gabrielson; Merry L Lindsey; Karel Pacak; Eiki Takimoto; Jean C Shih; David A Kass; Fabio Di Lisa; Nazareno Paolocci
Journal:  Antioxid Redox Signal       Date:  2013-05-22       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.